umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Cell Host and Microbe, ISSN 1931-3128, E-ISSN 1934-6069, Vol. 24, nr 3, s. 417-+Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Neutralizing antibodies (NAbs) are traditionally thought to inhibit virus infection by preventing virion entry into target cells. In addition, antibodies can engage Fc receptors (FcRs) on immune cells to activate antiviral responses. We describe a mechanism by which NAbs inhibit chikungunya virus (CHIKV), the most common alphavirus infecting humans, by preventing virus budding from infected human cells and activating IgG-specific Fc gamma receptors. NAbs bind to CHIKV glycoproteins on the infected cell surface and induce glycoprotein coalescence, preventing budding of nascent virions and leaving structurally heterogeneous nucleocapsids arrested in the cytosol. Furthermore, NAbs induce clustering of CHIKV replication spherules at sites of budding blockage. Functionally, these densely packed glycoprotein-NAb complexes on infected cells activate Fc gamma receptors, inducing a strong, antibody-dependent, cell-mediated cytotoxicity response from immune effector cells. Our findings describe a triply functional antiviral pathway for NAbs that might be broadly applicable across virus-host systems, suggesting avenues for therapeutic innovation through antibody design.

Ort, förlag, år, upplaga, sidor
Cell Press , 2018. Vol. 24, nr 3, s. 417-+
Nationell ämneskategori
Immunologi inom det medicinska området Mikrobiologi inom det medicinska området
Identifikatorer
URN: urn:nbn:se:umu:diva-152990DOI: 10.1016/j.chom.2018.07.018ISI: 000446887200013PubMedID: 30146390OAI: oai:DiVA.org:umu-152990DiVA, id: diva2:1260181
Forskningsfinansiär
NIH (National Institute of Health), R01 AI119056NIH (National Institute of Health), P41GM103832NIH (National Institute of Health), R24AI120942Tillgänglig från: 2018-11-01 Skapad: 2018-11-01 Senast uppdaterad: 2018-11-01Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Carlson, Lars-Anders

Sök vidare i DiVA

Av författaren/redaktören
Carlson, Lars-Anders
Av organisationen
Institutionen för medicinsk kemi och biofysik
I samma tidskrift
Cell Host and Microbe
Immunologi inom det medicinska områdetMikrobiologi inom det medicinska området

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 51 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf